Show simple item record

dc.creatorSoriano, Joan B
dc.creatorKendrick, Parkes J
dc.creatorPaulson, Katherine R
dc.creatorGupta, Vinay
dc.creatorAbrams, Elissa M
dc.creatorAdedoyin, Rufus Adesoji
dc.creatorAdhikari, Tara Ballav
dc.creatorAdvani, Shailesh M
dc.creatorAgrawal, Anurag
dc.creatorAlvis-Guzman, Nelson
dc.date.accessioned2021-01-05T21:45:07Z
dc.date.available2021-01-05T21:45:07Z
dc.date.issued2020-06
dc.identifier.issn0140-6736
dc.identifier.urihttps://hdl.handle.net/11323/7659
dc.description.abstractBackground Previous attempts to characterise the burden of chronic respiratory diseases have focused only on specific disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis on geographical and time trends from 1990 to 2017. Methods Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and occupational risks) to chronic respiratory disease-attributable DALYs. Findings In 2017, 544·9 million people (95% uncertainty interval [UI] 506·9–584·8) worldwide had a chronic respiratory disease, representing an increase of 39·8% compared with 1990. Chronic respiratory disease prevalence showed wide variability across GBD super-regions, with the highest prevalence among both males and females in high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex-specific prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory diseases were the third leading cause of death in 2017 (7·0% [95% UI 6·8–7·2] of all deaths), behind cardiovascular diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578–4 044 819) in 2017, an increase of 18·0% since 1990, while total DALYs increased by 13·3%. However, when accounting for ageing and population growth, declines were observed in age-standardised prevalence (14·3% decrease), agestandardised death rates (42·6%), and age-standardised DALY rates (38·2%). In males and females, most chronic respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region. Interpretation Our study shows that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health systems on a per-capita basis.spa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherCorporación Universidad de la Costaspa
dc.rightsCC0 1.0 Universal*
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.sourceThe Lancetspa
dc.subjectRespiratory diseasesspa
dc.subjectMorbidityspa
dc.subjectChronic obstructive pulmonary diseasespa
dc.subjectCOPDspa
dc.subjectAsthmaspa
dc.titlePrevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017spa
dc.typearticlespa
dcterms.references1 WHO. Chronic respiratory diseases. https://www.who.int/healthtopics/chronic-respiratory-diseases#tab=tab_1 (accessed May 22, 2020).spa
dcterms.references2 The Lancet. GBD 2017: a fragile world. Lancet 2018; 392: 1683.spa
dcterms.references3 WHO. Global Alliance against Chronic Respiratory Disease—About GARD. https://www.who.int/gard/en/ (accessed May 22, 2020).spa
dcterms.references4 WHO. Global surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach. http://www.who.int/gard/publications/GARD_Manual/en/ (accessed May 22, 2020).spa
dcterms.references5 Forum of International Respiratory Societies. The global impact of respiratory disease. 2nd edn. Sheffield: European Respiratory Society, 2017. https://www.who.int/gard/publications/The_Global_ Impact_of_Respiratory_Disease.pdf (accessed May 22, 2020).spa
dcterms.references6 Fingerhut M. Contribution of occupational risk factors to the global burden of disease. The Global Occupational Health Network, 2004. http://www9.who.int/occupational_health/publications/newsletter/ GohnetSpecialissue.pdf (accessed May 22, 2020).spa
dcterms.references7 Burney P, Perez-Padilla R, Marks G, Wong G, Bateman E, Jarvis D. Chronic lower respiratory tract diseases. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, eds. Disease control prioirities, 3rd edn. Vol 5: cardiovascular, respiratory, and related disorders. Washington, DC: World Bank, 2017.spa
dcterms.references8 Pearce N, Aït-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758–66.spa
dcterms.references9 European Respiratory Society. The economic burden of lung disease. In: European Lung White Book. https://www.erswhitebook.org/chapters/the-economic-burden-oflung-disease/ (accessed May 22, 2020).spa
dcterms.references10 Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691–706.spa
dcterms.references11 Salvi S, Kumar GA, Dhaliwal RS, et al. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health 2018; 6: e1363–74.spa
dcterms.references12 Yin P, Wang H, Vos T, et al. A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Chest 2016; 150: 1269–80.spa
dcterms.references13 Adhikari TB, Neupane D, Kallestrup P. Burden of COPD in Nepal. Int J Chron Obstruct Pulmon Dis 2018; 13: 583–89.spa
dcterms.references14 GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1736–88.spa
dcterms.references15 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–858.spa
dcterms.references16 GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1859–922.spa
dcterms.references17 GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1923–94.spa
dcterms.references18 Institute for Health Metrics and Evaluation. Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME, 2018. http://www.healthdata.org/policy-report/findings-global-burdendisease-study-2017 (accessed May 22, 2020).spa
dcterms.references19 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet 2016; 388: e19–23.spa
dcterms.references20 Flaxman AD, Vos T, Murray CJL. An integrative metaregression framework for descriptive epidemiology. University of Washington Press, 2015.spa
dcterms.references21 Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 Study. Lancet Glob Health 2015; 3: e712–23.spa
dcterms.references22 Brauer M, Freedman G, Frostad J, et al. Ambient Air Pollution Exposure Estimation for the Global Burden of Disease 2013. Environ Sci Technol 2016; 50: 79–88.spa
dcterms.references23 International Labour Organization. Key indicators of the labour market. http://www.ilo.org/ilostat/faces/ilostat-home/ (accessed Jan 17, 2019).spa
dcterms.references24 Jerrett M, Burnett RT, Pope CA, et al. Long-term ozone exposure and mortality. N Engl J Med 2009; 360: 1085–95.spa
dcterms.references25 Forouzanfar MH, Afshin A, Alexander LT, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1659–724.spa
dcterms.references26 Soriano JB, Ancochea J, Celli BR. The most beautiful COPD chart in the world: all together to end COPD! Eur Respir J 2019; 54: 1902047.spa
dcterms.references27 Hurst JR, Dickhaus J, Maulik PK, et al. Global Alliance for Chronic Disease researchers’ statement on multimorbidity. Lancet Glob Health 2018; 6: e1270–71.spa
dcterms.references28 Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2018; 198: 1130–39.spa
dcterms.references29 WHO. ‘Best Buys’ and other recommended interventions for the prevention and control of noncommunicable diseases. 2017. http://who.int/ncds/management/WHO_Appendix_BestBuys.pdf (accessed May 22, 2020).spa
dcterms.references30 GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017; 389: 1885–906.spa
dcterms.references31 Fernández E, López MJ, Gallus S, et al. Tackling second-hand exposure to tobacco smoke and aerosols of electronic cigarettes: the TackSHS project protocol. Gac Sanit 2020; 34: 77–82.spa
dcterms.references32 Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet 2018; 391: 350–400.spa
dcterms.references33 Topalovic M, Das N, Burgel PR, et al. Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. Eur Respir J 2019; 53: 1801660. 34 Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest 2015; 148: 971–85.spa
dcterms.references35 Bousquet JJ, Schünemann HJ, Togias A, et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy 2019; 9: 44.spa
dcterms.references36 Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literaturebased analysis. Lancet Respir Med 2019; 7: 687–98.spa
dcterms.references37 Perez-Padilla R. Hidden respiratory disease-associated deaths. Int J Tuberc Lung Dis 2008; 12: 458–64.spa
dcterms.references38 The Cigarette Century. The Rise, Fall, and Deadly Persistence of the Product That Defined America. Allan M Brandt. Cambridge, MA: Basic Books, 2009.spa
dcterms.references39 Christiani DC. Vaping-induced lung injury. N Engl J Med 2020; 382: 960–62.spa
dcterms.references40 Balakrishnan K, Dey S, Gupta T, et al. The impact of air pollution on deaths, disease burden, and life expectancy across the states of India: the Global Burden of Disease Study 2017. Lancet Planet Health 2019; 3: e26–39.spa
dcterms.references41 Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999; 340: 1881–87.spa
dcterms.references42 Lozano R, Fullman N, Abate D, et al. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 2091–138.spa
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersionspa
dc.source.urlhttps://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30105-3/fulltext#%20spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.identifier.doiDOI:https://doi.org/10.1016/S2213-2600(20)30105-3
dc.identifier.doi1474-547X


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC0 1.0 Universal
Except where otherwise noted, this item's license is described as CC0 1.0 Universal